Table 2. Open in new tab HRs for...

Variables	Hb^low	Hb^int	Hb^high
Overall
TNFi (ref) vs CTLA-4-Ig	0.72	0.52, 0.99	0.047	0.94	0.65, 1.35	0.73	0.63	0.44, 0.90	0.011
TNFi (ref) vs IL-6Ri	0.59	0.43, 0.83	0.002	0.72	0.51, 1.03	0.074	0.59	0.40, 0.86	0.007
TNFi (ref) vs JAKi	0.45	0.27, 0.76	0.003	0.89	0.53, 1.48	0.64	0.97	0.62, 1.50	0.88
Inefficacy
TNFi (ref) vs CTLA-4-Ig	0.64	0.42, 0.96	0.031	1.11	0.72, 1.70	0.62	0.66	0.43, 0.99	0.048
TNFi (ref) vs IL-6Ri	0.51	0.33, 0.77	0.001	0.60	0.38, 0.95	0.028	0.51	0.32, 0.81	0.005
TNFi (ref) vs JAKi	0.27	0.13, 0.60	0.001	0.87	0.47, 1.61	0.66	0.87	0.51, 1.48	0.61
Adverse events
TNFi (ref) vs CTLA-4-Ig	0.91	0.53, 1.56	0.72	0.61	0.29, 1.25	0.18	0.55	0.26, 1.15	0.11
TNFi (ref) vs IL-6Ri	0.79	0.46, 1.36	0.39	1.02	0.57, 1.82	0.95	0.83	0.42, 1.65	0.60
TNFi (ref) vs JAKi	0.85	0.41, 1.75	0.66	0.91	0.35, 2.38	0.85	1.26	0.56, 2.81	0.57

Variables

Hb^low

Hb^int

Hb^high

95% CI

P-value

95% CI

P-value

95% CI

P-value

Overall

TNFi (ref) vs CTLA-4-Ig

0.72

0.52, 0.99

0.047

0.94

0.65, 1.35

0.73

0.63

0.44, 0.90

0.011

TNFi (ref) vs IL-6Ri

0.59

0.43, 0.83

0.002

0.72

0.51, 1.03

0.074

0.59

0.40, 0.86

0.007

TNFi (ref) vs JAKi

0.45

0.27, 0.76

0.003

0.89

0.53, 1.48

0.64

0.97

0.62, 1.50

0.88

Inefficacy

TNFi (ref) vs CTLA-4-Ig

0.64

0.42, 0.96

0.031

1.11

0.72, 1.70

0.62

0.66

0.43, 0.99

0.048

TNFi (ref) vs IL-6Ri

0.51

0.33, 0.77

0.001

0.60

0.38, 0.95

0.028

0.51

0.32, 0.81

0.005

TNFi (ref) vs JAKi

0.27

0.13, 0.60

0.001

0.87

0.47, 1.61

0.66

0.87

0.51, 1.48

0.61

Adverse events

TNFi (ref) vs CTLA-4-Ig

0.91

0.53, 1.56

0.72

0.61

0.29, 1.25

0.18

0.55

0.26, 1.15

0.11

TNFi (ref) vs IL-6Ri

0.79

0.46, 1.36

0.39

1.02

0.57, 1.82

0.95

0.83

0.42, 1.65

0.60

TNFi (ref) vs JAKi

0.85

0.41, 1.75

0.66

0.91

0.35, 2.38

0.85

1.26

0.56, 2.81

0.57

Variables	Hb^low	Hb^int	Hb^high
Overall
TNFi (ref) vs CTLA-4-Ig	0.72	0.52, 0.99	0.047	0.94	0.65, 1.35	0.73	0.63	0.44, 0.90	0.011
TNFi (ref) vs IL-6Ri	0.59	0.43, 0.83	0.002	0.72	0.51, 1.03	0.074	0.59	0.40, 0.86	0.007
TNFi (ref) vs JAKi	0.45	0.27, 0.76	0.003	0.89	0.53, 1.48	0.64	0.97	0.62, 1.50	0.88
Inefficacy
TNFi (ref) vs CTLA-4-Ig	0.64	0.42, 0.96	0.031	1.11	0.72, 1.70	0.62	0.66	0.43, 0.99	0.048
TNFi (ref) vs IL-6Ri	0.51	0.33, 0.77	0.001	0.60	0.38, 0.95	0.028	0.51	0.32, 0.81	0.005
TNFi (ref) vs JAKi	0.27	0.13, 0.60	0.001	0.87	0.47, 1.61	0.66	0.87	0.51, 1.48	0.61
Adverse events
TNFi (ref) vs CTLA-4-Ig	0.91	0.53, 1.56	0.72	0.61	0.29, 1.25	0.18	0.55	0.26, 1.15	0.11
TNFi (ref) vs IL-6Ri	0.79	0.46, 1.36	0.39	1.02	0.57, 1.82	0.95	0.83	0.42, 1.65	0.60
TNFi (ref) vs JAKi	0.85	0.41, 1.75	0.66	0.91	0.35, 2.38	0.85	1.26	0.56, 2.81	0.57

Table 2.

Open in new tab

HRs for discontinuation due to inefficacy and adverse events in each Hb group (Hb^low, Hb^int, Hb^high)

Variables	Hb^low			Hb^int			Hb^high
Variables	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Overall
TNFi (ref) vs CTLA-4-Ig	0.72	0.52, 0.99	0.047	0.94	0.65, 1.35	0.73	0.63	0.44, 0.90	0.011
TNFi (ref) vs IL-6Ri	0.59	0.43, 0.83	0.002	0.72	0.51, 1.03	0.074	0.59	0.40, 0.86	0.007
TNFi (ref) vs JAKi	0.45	0.27, 0.76	0.003	0.89	0.53, 1.48	0.64	0.97	0.62, 1.50	0.88
Inefficacy
TNFi (ref) vs CTLA-4-Ig	0.64	0.42, 0.96	0.031	1.11	0.72, 1.70	0.62	0.66	0.43, 0.99	0.048
TNFi (ref) vs IL-6Ri	0.51	0.33, 0.77	0.001	0.60	0.38, 0.95	0.028	0.51	0.32, 0.81	0.005
TNFi (ref) vs JAKi	0.27	0.13, 0.60	0.001	0.87	0.47, 1.61	0.66	0.87	0.51, 1.48	0.61
Adverse events
TNFi (ref) vs CTLA-4-Ig	0.91	0.53, 1.56	0.72	0.61	0.29, 1.25	0.18	0.55	0.26, 1.15	0.11
TNFi (ref) vs IL-6Ri	0.79	0.46, 1.36	0.39	1.02	0.57, 1.82	0.95	0.83	0.42, 1.65	0.60
TNFi (ref) vs JAKi	0.85	0.41, 1.75	0.66	0.91	0.35, 2.38	0.85	1.26	0.56, 2.81	0.57

Variables	Hb^low			Hb^int			Hb^high
Variables	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Overall
TNFi (ref) vs CTLA-4-Ig	0.72	0.52, 0.99	0.047	0.94	0.65, 1.35	0.73	0.63	0.44, 0.90	0.011
TNFi (ref) vs IL-6Ri	0.59	0.43, 0.83	0.002	0.72	0.51, 1.03	0.074	0.59	0.40, 0.86	0.007
TNFi (ref) vs JAKi	0.45	0.27, 0.76	0.003	0.89	0.53, 1.48	0.64	0.97	0.62, 1.50	0.88
Inefficacy
TNFi (ref) vs CTLA-4-Ig	0.64	0.42, 0.96	0.031	1.11	0.72, 1.70	0.62	0.66	0.43, 0.99	0.048
TNFi (ref) vs IL-6Ri	0.51	0.33, 0.77	0.001	0.60	0.38, 0.95	0.028	0.51	0.32, 0.81	0.005
TNFi (ref) vs JAKi	0.27	0.13, 0.60	0.001	0.87	0.47, 1.61	0.66	0.87	0.51, 1.48	0.61
Adverse events
TNFi (ref) vs CTLA-4-Ig	0.91	0.53, 1.56	0.72	0.61	0.29, 1.25	0.18	0.55	0.26, 1.15	0.11
TNFi (ref) vs IL-6Ri	0.79	0.46, 1.36	0.39	1.02	0.57, 1.82	0.95	0.83	0.42, 1.65	0.60
TNFi (ref) vs JAKi	0.85	0.41, 1.75	0.66	0.91	0.35, 2.38	0.85	1.26	0.56, 2.81	0.57

Adjusted confounders included baseline age, disease duration, number of previous bDMARDs administered, PSL use and MTX use.

Hb^low: male Hb <12.0 g/dL, female Hb <11.4 g/dL; Hb^int: male ≥12.0–<13.7 g/dL, female ≥11.4–<12.6 g/dL; Hb^high: male Hb ≥13.7 g/dL, female Hb ≥12.6 g/dL.

This Feature Is Available To Subscribers Only